Implementation of a patient-facing genomic test report in the electronic health record using a web-application interface

Marc S. Williams1*, Melissa S. Kern2, Virginia R. Lerch3, Jonathan Billet3, Janet L. Williams1 and Gregory J. Moore3

Abstract

Background: Genomic medicine is emerging into clinical care. Communication of genetic laboratory results to patients and providers is hampered by the complex technical nature of the laboratory reports. This can lead to confusion and misinterpretation of the results resulting in inappropriate care. Patients usually do not receive a copy of the report leading to further opportunities for miscommunication. To address these problems, interpretive reports were created using input from the intended end users, patients and providers. This paper describes the technical development and deployment of the first patient-facing genomic test report (PGR) within an electronic health record (EHR) ecosystem using a locally developed standards-based web-application interface.

Methods: A patient-facing genomic test report with a companion provider report was configured for implementation within the EHR using a locally developed software platform, COMPASS™. COMPASS™ is designed to manage secure data exchange, as well as patient and provider access to patient reported data capture and clinical display tools. COMPASS™ is built using a Software as a Service (SaaS) approach which exposes an API that apps can interact with.

Results: An authoring tool was developed that allowed creation of patient-specific PGRs and the accompanying provider reports. These were converted to a format that allowed them to be presented in the patient portal and EHR respectively using the existing COMPASS™ interface thus allowing patients, caregivers and providers access to individual reports designed for the intended end user.

Conclusions: The PGR as developed was shown to enhance patient and provider communication around genomic results. It is built on current standards but is designed to support integration with other tools and be compatible with emerging opportunities such as SMART on FHIR. This approach could be used to support genomic return of results as the tool is scalable and generalizable.

Keywords: Genomics, Medical informatics applications, Electronic health records, Patient-centered care, Patient access to records, Communication

Background

Precision Medicine with an emphasis on the incorporation of genomic information into the clinic has been identified as a priority for research in the United States [1].

Genetic disorders, while individually rare, are collectively common. It is estimated that there are over 6800 rare and ultra-rare disorders, many of which are genetic affecting approximately 30 million Americans [2]. The challenge for patients and their providers is having ready access to the information that is necessary for appropriate management and coordination of care. When faced with a patient with a genetic condition they have not previously encountered, knowledge and resources are extremely limited. This often puts patients and families in the position of attempting to become the ‘expert’ in the specific disease via an unguided internet search process which can lead to uncomfortable and sometimes adversarial encounters with the medical system.

One potential solution to lower the barriers experienced by providers caring for patients with genetic
conditions is using fully functional electronic health record systems (EHR) [3–5]. The capabilities provided by such EHRs, particularly through knowledge management systems and clinical decision support systems, have been demonstrated to significantly improve process outcomes, although the evidence of impact on health outcomes is less robust [6].

While these techniques have mostly faced toward providers, similar approaches could be used to provide information directly to patients and families. A recent study conducted at 3 healthcare organizations, including Geisinger, studied the impact of opening patient access to their provider notes through a secure patient portal (OpenNotes) [7]. Using a quasi-experimental trial design, several significant differences were noted when comparing the pre- and post-intervention surveys including patients reporting that OpenNotes, “...helped them feel more in control of their care” and “...increased medication adherence.”. A recent article noted that patient-facing applications could enable meaningful use objectives promoted by the Office of the National Coordinator of Health Information Technology (ONCHIT) [8]. This approach is also endorsed by the recent report from the National Academy of Medicine (formerly the Institute of Medicine), Improving Diagnosis in Health Care [9] which highlights the importance of patient empowerment.

One area that has received less emphasis is the role of the laboratory report in communicating information to patients. Haga et al. [10] propose four revisions to current genomic test reports that could improve accessibility for patients. These include, “...1) inclusion of an interpretive summary section, 2) a summary letter to accompany the lab report, 3) development of a patient user guide to be provided with the report, and 4) a completely revised patient-friendly report.” In genomic medicine, direct-to-consumer companies have emerged that provide results of tests to consumers without the intermediary of a health care professional. While many of the results are non-health related (e.g. ancestry) some companies are returning predictive information that could have an impact on an individual’s health. The positive and negative outcomes of providing this information directly to consumers have not been rigorously studied.

Our group has previously reported on the design and testing of linked patient- and provider-facing genomic test reports [11, 12]. These reports are not meant to replace the laboratory report, but to provide additional information to guide interpretation and clarify clinical recommendations that result from the testing. As such they are compatible with the recommendation from Haga to create a “a patient-friendly report” [10]. A comparative effectiveness study [13] that compares the use of these reports to standard of care communication has recently concluded and demonstrates qualitative improvement in communication and satisfaction.

The purpose of this paper is to present the technical aspects of development and deployment of the first patient-facing genomic test report (PGR) within an EHR ecosystem using a locally developed web-application interface.

**Methods**

A PGR was developed using a mixed-methods formative approach which has been previously reported [11]. The PGR includes content that was considered important by patients and their families. The content is vetted for readability through a review process that includes content experts, non-genetic providers and patients and is formally tested to meet accepted literacy standards. The PGR was developed using paper mock-ups. Once the final format was chosen, this was converted to an electronic format that could be displayed through an interface such as a patient portal, but could also be printed to provide a hard copy. A similar process was used to create a provider version of the PGR that was designed to complement the PGR [12]. These two reports were then submitted to the COMPASS™ development team for implementation.

COMPASS™ is a software platform developed at Geisinger intended to work as an add-on to EHRs. Its main purpose is to manage secure data exchange, as well as patient and provider access to patient reported data capture and clinical display tools utilized within Geisinger. It is intended to improve patient engagement in their care and enhance patient-provider communication.

COMPASS™ is built using the ASP.Net framework where the presentation layer (User Interface) implements web development languages and libraries including HTML, CSS, JavaScript, Jquery, AngularJS, and Angular2. The back-end (Code Behind, Logic, Data Interactions) is coded using C# and utilizes SQL Data Adapters, SOAP Web Services, WebAPIs, and Teradata Data Adapters to facilitate data transfers. The COMPASS™ data model utilizes MS SQL Server but it is not limited to only utilizing SQL Server for interacting with data as it can consume data from web services or any standard database platform through its Software as a Service (SaaS) approach. Through this, users can either pass data to the COMPASS™ API for use or COMPASS™ can access common database platforms and consume/display appropriate data. It is designed so that any content can be coded to be accessible on any other resource. This allows content in COMPASS™ to be agnostic from its own server/resource perspective.

COMPASS™ is integrated with Geisinger’s primary EHR (Epic) on several levels. The EHR interacts with COMPASS™ by launching an external web browser via a
specific encrypted URL. The current implementation within Epic is a visit navigator link which contains required encrypted parameters for authentication. COMPASS™ is fed by real-time data feeds from the EHR to correctly determine project inclusion/exclusion and display correct and current data to users. Currently, the real time feeds that COMPASS™ utilizes are custom and standard data extractions that interface with Epic. COMPASS™ is also integrated with patient portals (currently MyGeisinger which is a MyChart implementation) so patients can use the application when off-site from the health system network. As with the EHR, COMPASS™ interacts with the portal by launching an external web browser via an encrypted URL.

An authoring application was created within COMPASS™ to assist geneticists and genetic counselors with building coordinated and complementary patient and family-facing and provider-facing reports of the patient’s test results. The authoring application includes areas to create and store generic genetic content for the reports that is not readily available from other sources. The authoring environment contains reusable content fields (including inheritance patterns, glossary terms and gene templates that create gene-specific content that can be used for all reports that return results related to the gene) that can be selected to populate patient and provider reports. The environment tracks versioning of the information created within the authoring application—an essential element given the rapidly changing nature of knowledge in genomics that can have implications for liability. The ecosystem of the PGR report is presented in Fig. 1.

A patient report template is used by the geneticist/counselor to pull information together to create the patient specific reports. Through COMPASS™, the patient report template interfaces with various data sources in addition to the database storing the information generated from the generic gene template (Fig. 2), inheritance pattern template, and glossary term template. One specific tool, the SimulConsult® Genome-Phenome Analyzer (SGPA) [14] has been used to provide information to the report. A local API is called when a user finishes creating the content for the custom report in the authoring environment. The author then opens the Epic record for the patient and launches the SGPA from the encounter navigator. In the SGPA, patient information is combined with the genomic sequence information and a gene associated with the clinical features along with a variant in that gene are selected by the author. This ‘closes the loop’ by associating the gene and variant with the specific patient. The author then clicks the “Send XML Report” button in the SGPA which sends SimulConsult® content back to the authoring environment. A custom parser developed to support the project, in combination with the SimulConsult® Web API loads the data into the “PatientReports” table in the Genomics database. The final patient-specific report is available for review and publication at which time it appears in the MyGeisinger patient portal, and is accessible to clinicians in the patient’s encounter navigator through a local Web Apps URL. One specific example of SGPA content that was highly valued by both patients and providers was the prognosis table. This prognosis table, which summarizes medical issues associated with a condition the likelihood that the issue will develop and when in the life of the patient they are likely to appear, is automatically generated by the SGPA [14]. The manual creation of such a table would require a tremendous

FIG. 1 COMPASS™ Data Flow. A diagram of the data flows for COMPASS™. Note that the EHR data flow is in the process of moving to SMART on FHIR which should increase the generalizability of the tool in different EHR ecosystems.
investment of time and expertise. While not required for the authoring process, use of the SGPA improves the workflow and reduces the time needed to author a report. Upon selection and verification of the content, the report content is published from the authoring application and made available to patients and their families and providers electronically in COMPASS™.

**Results**

After the PGR is generated in the authoring application of COMPASS™, the author will publish the report so that it is available to patients and their authorized representatives (usually family members). Patients and their families can access the report electronically through a link out to COMPASS™ from the patient’s MyGeisinger portal or prior to a visit in the clinic during the nurse rooming process in Epic (Fig. 3). The PGR is also designed so that a hard copy can be printed—a requirement that was requested by participants in the formative study. The report is written and laid out in a manner based on input from the interviews and focus groups that reflects the preferences of these end users. It presents the reason for genetic testing, information about the gene(s), variant(s)
and associated diagnoses, prognosis, information for other family members, a glossary of genetic terminology, and resources to learn more such as disorder-specific support groups and sites designed for lay persons like Genetics Home Reference (Fig. 4). To promote engagement and empowerment, information is also provided about possible clinical trials relevant to the disorder (clinicaltrials.gov) and services such as GenomeConnect that support patient/family entered data to facilitate networking and research. Full details about the report are published elsewhere [11].

The provider-facing report (Fig. 5) is also made available at the point of care to primary care and genetic specialty providers who have access to COMPASS™ in Epic. COMPASS™ is embedded in the provider’s workflow in Epic in the visit navigator section and is designed to either be a manually or automatically launched depending on the clinic site’s needs. This report does not replace the actual laboratory report which is still scanned into the patient record (and is accessible through a link from the provider-facing report). It is meant to supplement the laboratory report to assist providers as they interpret the results and use them to guide care. This draft report was presented to providers and input from the providers was used to modify the draft [12]. The provider report includes standard information such as demographics, clinical data and testing information. The report highlights the indication for genetic testing, key findings, primary and secondary diagnoses and variant information, any genes that were found that require more research before conclusions can be drawn, a glossary of genetic terminology, and provider focused resources to learn more such as GeneReviews and Online Mendelian Inheritance in Man. The providers requested access to the PGR so that they are aware of information provided to the patients and their families. Access to the PGR is through a link within the provider report.

One additional enhancement that was added after the final reports were developed was the inclusion of infobuttons. Infobuttons are context-sensitive links embedded within information systems which allow easy retrieval of relevant information. They use contextual information about the patient, user, clinical setting, and EHR task to anticipate providers’ information needs and provide links to online clinical resources that may meet these information needs. While primarily directed to
Primary Findings

What Are Primary Findings?
At this time we looked for the genes that might explain your symptoms. As time goes on, we may be able to look at other genes and other conditions.

Summary of Results
A genetic cause for symptoms was found with a diagnosis of Rett syndrome. It is important to talk with your doctor about the meaning of these results.

Information about the MECP2 Gene

What does this gene do?
MECP2 produces a protein that binds to sections of DNA that have undergone methylation. This allows regulation of gene transcription. It is required for maturation of neurons (brain cells).

What variant(s) were found?
- NM_001170712; c.856C>T; R316C p.316R=C

How do variants in this gene cause health problems?
Variants in MECP2 alter its function which results in abnormal gene regulation. This leads to problems with neuronal maturation and brain development leading to intellectual disability and seizures. The most common disorder associated with variants in MECP2 is Rett syndrome which is seen only in girls. After birth, girls with classic Rett syndrome have 6 to 18 months of apparently normal development before developing severe problems with language and communication, learning, coordination, and other brain functions. Early in childhood, affected girls lose purposeful use of their hands and begin making repeated hand wringing, washing, or clapping motions. They tend to grow more slowly than other children and have a small head size (microcephaly). Other signs and symptoms that can develop include breathing abnormalities, seizures, an abnormal side-to-side curvature of the spine (scoliosis), and sleep disturbances. Occasionally boys with variants in MECP2 develop signs and symptoms similar to those of Rett syndrome, including intellectual disability, seizures, and movement problems. In males, this condition is described as MECP2-related severe neonatal encephalopathy. Recently variants in MECP2 that are milder have been associated with intellectual disability and autism.

Are the variants the cause of the symptoms?
This variant is the cause of your symptoms because: Variants in MECP2 have been identified in a number of neurodevelopmental disorders that mostly affect girls. These include classic Rett syndrome, atypical Rett syndrome which includes types with preserved expressive language, and milder forms of intellectual disability and autism. MECP2 mutations are usually lethal in boys, however there are reports of boys with MECP2 variants with severe neonatal encephalopathy usually resulting in death in early childhood. Girls with classic Rett syndrome have 6 to 18 months of apparently normal development before developing severe problems with language and communication, learning, coordination, and other brain functions. Early in childhood, affected girls lose purposeful use of their hands and begin making repeated hand wringing, washing, or clapping motions. They tend to grow more slowly than other children and have a small head size (microcephaly). Other signs and symptoms that can develop include breathing abnormalities, seizures, an abnormal side-to-side curvature of the spine (scoliosis), and sleep disturbances. In most cases mutations are de novo although rare cases of multiple affected family members have been reported.

The Cause of Symptoms

| Suspected | Probably Pathogenic | Pathogenic |

Specific Issues to Discuss with Your Doctor

Treatment options and current care
- Unusual movements or episodes of staring or unresponsiveness should be evaluated for possible seizures.
- If severe breathing problems are present evaluation by a pulmonary specialist and respiratory therapist are needed to identify the best treatment options.

Support services
- Early childhood intervention and special education services.
- A total communication program may be needed given difficulties with speech and expressive language.
- Respiratory therapy and devices that assist breathing and oxygen may be needed in children with severe respiratory problems.

Monitoring
- Careful monitoring of seizure activity is needed to achieve good seizure control.

Fig. 4 The published patient report: Primary finding detail. Shows the first portion of the report on the primary finding, in this case a pathogenic variant in the MECP2 gene.
providers, there are emerging use cases that include infobuttons in patient-facing applications. Our enhancement took advantage of the emergence of OpenInfobutton, an open source suite of Web services that enable infobutton capabilities within EHR systems [15]. Use of this open source standard and its supporting resources allowed incorporation of the functionality into the PGR with minimal effort from the development team using the SaaS functionality in COMPASS. This was a high value addition to the report given that the Clinical

| Summary of Findings |
|----------------------|
| **Reason for Testing** |
| Whole genome sequencing testing was ordered to identify a possible genetic cause for your symptoms. Your symptoms were reported to include intellectual disability, seizures with abnormal movements, and stereotypies. |
| **Other Key Clinical Findings** |
| None |
| **Primary Findings** |
| **MECP2** |
| **Clinical Diagnosis:** A genetic cause for symptoms was found with a diagnosis of Palli syndrome. |
| **Rationale:** Variants in MECP2 have been identified in a number of neurodevelopmental disorders that mostly affect girls. These include classic Rett syndrome, atypical Rett syndrome, which includes types with preserved expressive language, and milder forms of intellectual disability and autism. MECP2 mutations are usually lethal in boys, however there are reports of boys with MECP2 variants with severe neonatal encephalopathy usually resulting in death in early childhood. Girls with classic Palli syndrome have 5 to 18 months of apparently normal development before developing severe problems with language and communication, learning, coordination, and other brain functions. Early in childhood, affected girls lose purposeful use of their hands and begin making repeated hand wringing, washing, or clapping motions. They tend to grow more slowly than other children and have a small head size (microcephaly). Other signs and symptoms that can develop include breathing abnormalities, seizures, an abnormal side-to-side curvature of the spine (scoliosis), and sleep disturbances. In most cases mutations are de novo although rare cases of multiple affected family members have been reported. |
| **Pertinent positives:** |
| Intellectual disability |
| Seizures with abnormal movements |
| Stereotypies |
| **Pertinent negatives:** |
| **Mode of Inheritance:** de novo |
| **Variants found:** |
| NM_00115752.2: c.550G>T, rs216308.1p.182R>G Monosodium mismatch |
| **Additional Findings** |
| **BRCA2** |
| **Rationale:** Adults with BRCA syndrome are at a higher risk to develop breast, ovarian and other cancers than people in the general population. Childhood cancers are NOT known to be associated with BRCA. Some families with HBOC syndrome also have a higher risk for certain other cancers, such as melanoma or pancreatic cancer. While it is possible to have HBOC and never develop cancer, it is important for anyone who has HBOC to follow specific early cancer screening and prevention guidelines. |
| **Mode of Inheritance:** Terti Autosomal Dominant |
| **Variants found:** |
| NM_000059.2: c.2779+2>T, rs132279341.1p.182R>G Monosodium mismatch |
| **Confirmatory testing:** Whole genome sequencing findings have been confirmed using a standard sequencing method |

**Fig. 5** The published provider report: Summary. This shows the provider view of the summary of findings. As with the patient report, the provider can drill down for additional information on both the primary and additional findings for the patient. In addition, the provider can link to the SimulConsult® patient summary, access the report issued by the testing laboratory and can view (but not edit) the full content of the patient report.
Genome resource, which aggregates genetic and genomic information from a variety of sources, is accessible through OpenInfobutton [16].

Discussion

The formative work that preceded development of the tool identified the need for such a tool as well as the elements that were needed for inclusion. The prototype underwent beta testing in the EHR and patient portal environments to identify and fix any technical problems that interfere with the tool’s access, performance, and usability. The tool was deployed as part of a prospective randomized comparative effectiveness trial [13]. This trial used participants in a clinical research project that is using whole genome sequencing to determine the cause of undiagnosed intellectual disability. The trial was recently completed and confirmed that the report improved satisfaction, engagement, and enhanced communication compared to standard of care for those participants where a causal variant was found. Qualitative evaluation identified some technical issues that initially limited accessibility of the PGR. When the PGR was launched for a patient, the message generated by the MyGeisinger portal was a default generic message that notified the recipient that a survey was available. This was confusing and led many patients to delete the message without accessing the report. A customized message has been developed to solve this issue. Another problem was when the intended recipient was a caregiver of the patient, the caregiver had to have proxy access to the MyGeisinger portal to receive the message and launch the PGR. Proxy access is now addressed during the clinical encounter where the results are reported and caregivers are given instructions to create proxy access.

While the tool has been developed as part of a larger project involving whole genome sequencing, the tool could be used to supplement traditional genetic test reports as well. The tool also has the potential to support large scale sequencing projects with return of results. Geisinger is partnering with the Regeneron Genetics Center to perform exome sequencing on as many as 250,000 Geisinger patients over the next 5 years [17]. Over 90,000 exomes are already completed and analysis to identify pathogenic variants in genes that have been determined to have clinical actionability (such as \textit{BRCA1} and \textit{BRCA2}, \textit{LDLR}, etc.) [18]. The PGR is being used to support the clinical reporting of actionable genomic findings. As of December 2017, over 500 clinical reports have been issued. PGRs have been issued for 61 participants and their providers with the remaining 500 prioritized for release over the next 3 months. Going forward, the clinical reporting process has been modified such that GPRs will be issued when the participant is contacted. The large number of reports will allow robust evaluation and improvement. In addition, a pharmacogenomic (PGx) PGR has been developed [19]. Because PGx results are quite different from causal Mendelian genetic variants, the PGx PGR was developed using the same end user engagement approach as the PGR described here and elsewhere. Additional use cases are being explored.

Demonstration of compatibility with other tools such as the SGPA enhances the utility and generalizability of the PGR tool. This implementation required a significant amount of effort from personnel at both sites as it required development of novel interfaces and customized local solutions. Standards-based approaches would be desirable to allow more rapid enhancements such as was used to incorporate OpenInfobutton functionality, which required very little developer time and no local customization. Recently, SMART on FHIR has been touted as a new approach that will enable “plug-in apps” to run natively inside any compliant EHR [20]. The HL7-developed FHIR standards are designed to support retrieval of data services needed to drive applications, while the SMART platform is designed to launch from the EHR and facilitate the launching of apps, all within extant clinical workflows. Combined with OAuth2 authorization, the SMART on FHIR platform provides a standards-based technology stack for app development. Geisinger is currently exploring usage of SMART on FHIR capabilities in platforms and applications including COMPASS™. Most relevant to the PGR, SMART on FHIR Genomics is emerging as a genomic-specific HL7 approved standard [21]. The feasibility of the prototype was demonstrated through incorporation in three representative applications based on the SMART platform. Recently, SMART on FHIR Genomics has been selected for use in the All of Us program (previously the Precision Medicine Initiative) through the Sync for Genes project [22]. Incorporating the functionality of SMART on FHIR Genomics into the PGR is being explored. As adoption of these standards increases, so will the potential scalability and portability of current and future web applications such as the PGR.

Conclusions

In conclusion, we believe that to realize the promise of genomic and ultimately precision medicine requires increased engagement with patients and their caregivers. The PGR represents the first effort to develop and implement a tool to engage patients and their providers within the EHR ecosystem. It addresses currently identified barriers and implements all the elements of the ONCHIT Self-care and Community domains [8].
Acknowledgements

Thanks to all the patient, their families, and providers that participated in the development of the reports. We also acknowledge the significant contributions of the SimulConsult team, particularly Lynn Feldman and Michael Segal.

Funding

Funded through Patient Centered Outcomes Research Institute; PCORI Contract Number: CD-1304-6987. Project title: Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients. The funder had no role in the design of the study, collection, analysis and interpretation of data, or writing the manuscript.

Availability of data and materials

The COMPASS® software and interface was constructed using open source standards as described in the materials and methods. Questions about the technical details or implementation can be directed to the corresponding author. The SimulConsult® Genome Phenome Analyzer (SGPA) is a proprietary software tool. As a result, the PGR that is integrated with the SGPA is not available for distribution. Inquiries about SGPA can be directed to Dr. Michael Segal, or Lynn Feldman, by e-mail contact YYYY@simulconsult.com. The SGPA is not available for distribution. Inquiries about SGPA can be directed to Dr. Michael Segal, or Lynn Feldman, by e-mail contact YYYY@simulconsult.com where YYYY is the year. In the subject line, state the intended recipient (person or role). Additional information on this software is available at www.simulconsult.com.

Authors’ contributions

All authors participated in the drafting, review and approval of the manuscript. MSW and JLW conceived the project and led the design efforts. GJM contributed to the conceptual design of the tool and supervised the implementation and participated in the design decisions. All authors have reviewed and approved the final manuscript.

Ethics approval and consent to participate

Participants involved in the development of the tool provided written consent to participate. This study was approved by the Geisinger Institutional Review Board Registration # 00008354.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Genomic Medicine Institute, Geisinger, 100 North Academy Avenue, Danville, PA, USA. 2 Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA. 3 Institute for Advanced Application, Geisinger, Danville, PA, USA.

Received: 2 May 2017 Accepted: 22 May 2018

References

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.
2. Rare Disease Information. National Organization for Rare Disorders. http://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/ Accessed 16 Dec 2017.
3. Hoffman MA, Williams MS. Electronic medical records and personalized medicine. Hum Genet. 2011;130(1):33–9.
4. Kullo IJ, Jarvik GP, Manolio TA, et al. Leveraging the electronic health record to implement genomic medicine. Genet Med. 2013;15(4):208–67.
5. Manolio TA, Chisolm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15(4):208–67.
6. Lobach D, Sanders GD, Bright TJ, et al. Enabling health care decision making through clinical decision support and knowledge management. Evid Rep Technol Assess. 2012;2003:1–84.
7. Delbanco T, Walker J, Bell SK, et al. Inviting patients to read their doctors’ notes: a quasi-experimental study and a look ahead. Ann Intern Med. 2012; 157:461–70.
8. Ahern DK, Woods SS, Lightowler MC, et al. Promise of potential for patient-facing technologies to enable meaningful use. Am J Prev Med. 2011;40(Suppl 2):S162–72.
9. National Academies of Sciences, Engineering, and Medicine. Improving Diagnosis in Health Care. Washington, DC: The National Academies Press; 2015. https://doi.org/10.17226/21794. Accessed 16 Dec 2017.
10. Haga SB, Mills R, Pollák KI, et al. Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding. Genome Med. 2014;6(7):58.
11. Stuckey H, Williams JL, Fan AL, et al. Enhancing genomic laboratory reports from the patients’ view: a qualitative analysis. Am J Med Genet A. 2015;167A(10):2238–43.
12. Williams JL, Rahm AK, Stuckey H, et al. Enhancing genomic laboratory reports: a qualitative analysis of provider review. Am J Med Genet A. 2016; 170A(5):113–41.
13. Williams JL, Rahm AK, Zallen DT, et al. Impact of a patient-facing enhanced genomic results report to improve understanding, engagement, and communication. J Genet Couns. 2017. doi: https://doi.org/10.1007/s10897-017-0176-6. [Pub ahead of print].
14. http://simulconsult.com/genome/index.html. Accessed 16 Dec 2017.
15. http://www.openinfobutton.org/. Accessed 16 Dec 2017.
16. Heale BSE, Overby CL, Del Fiol G, et al. Integrating genomic resources with electronic health records using the HL7 Infobus standard. Appl Clin Inform. 2016;3(1):31–37.
17. Carey DJ, Fetterolf SN, Davis FO, et al. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet Med. 2016;18(9):906–13.
18. Dewey FE, Murray MF, Overton JD, et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science. 2016;354(6319):6173–65.
19. Jones LR, Rahm AK, Gionfriddo MR, et al. Developing pharmacogenomic reports: insights from patients and clinicians. Clin Transl Sci. 2018;11(3):289–95.
20. Something New and Powerful: SMART on FHIR. 2015. http://smarthealthit.org/smart-on-fhir/ Accessed 16 Dec 2017.
21. Alterovitz G, Warner J, Zhang P, et al. SMART on FHIR genomics: facilitating standardized clinico-genomic apps. J Am Med Inform Assoc. 2015;22(6):1173–8.
22. https://www.healthcare-informatics.com/article/interoperability/sync-genes-complement-sync-science. Accessed 16 Dec 2017.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions